| Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach F Antoñanzas, CA Juárez-Castelló, R Rodríguez-Ibeas Health Economics, Policy and Law 6 (3), 391-403, 2011 | 58 | 2011 |
| The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments F Antonanzas, CA Juárez-Castelló, R Lorente, R Rodríguez-Ibeas PharmacoEconomics, 1-15, 2019 | 56 | 2019 |
| Transferability indices for health economic evaluations: methods and applications FA VILLAR, F HUTTER, R RODRÍGUEZ-IBEAS, M PINILLOS, ... Health Economics 18 (6), 629-643, 2009 | 50 | 2009 |
| Impacto del Real Decreto-Ley 16/2012 sobre el copago farmacéutico en el número de recetas y en el gasto farmacéutico F Antoñanzas Villar, R Rodríguez-Ibeas, CA Juárez-Castelló, ... Revista española de salud pública 88 (2), 233-249, 2014 | 38* | 2014 |
| Costes de la insuficiencia cardiaca crónica en España FA VILLAR, F ANTÓN, CA JUÁREZ-CASTELLÓ, L ECHEVERRÍA . Anales de Medicina Interna 14 (1), 9-14, 1997 | 38 | 1997 |
| Economic aspects of the new Spanish laws on pharmaceutical preparations F Antoñanzas, J Oliva, M Pinillos, C Juàrez The European Journal of Health Economics 8 (3), 297-300, 2007 | 24 | 2007 |
| Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails? F Antoñanzas, R Rodríguez-Ibeas, CA Juárez-Castelló PharmacoEconomics 36 (7), 733-743, 2018 | 23 | 2018 |
| Some economics on personalized and predictive medicine F Antoñanzas, CA Juárez-Castelló, R Rodríguez-Ibeas The European Journal of Health Economics 16 (9), 985-994, 2015 | 23 | 2015 |
| Genetic testing in the European Union: does economic evaluation matter? F Antoñanzas, R Rodríguez-Ibeas, MF Hutter, R Lorente, C Juárez, ... The European Journal of Health Economics 13 (5), 651-661, 2012 | 22 | 2012 |
| Cálculo de los costes del sida en España mediante técnicas de simulación F Antoñanzas Villar, F Anton Botella, CA Juárez-Castelló Medicina clínica 104 (15), 568-572, 1995 | 22* | 1995 |
| Impacto de los estudios de evaluación económica en la toma de decisiones sanitarias en el ámbito hospitalario Rovira, J. Juárez Castelló, Carmelo Arturo. Figueras, M. Del Llano, J. Oliva ... Gestión Hospitalaria 4 (11), 171-179, 2000 | 18* | 2000 |
| Impacto de los estudios de evaluación económica en la toma de decisiones sanitarias en Atención Primaria. J OLIVA, JDEL LLANO, FA VILLAR, CA Juárez-Castelló, J ROVIRA, ... Cuadernos de Gestión para el Profesional de Atención Primaria 7 (4), 2001 | 17 | 2001 |
| Impact of the studies of economic evaluation in the health care decision-making CAJ Castelló, FJA Villar XX Jornadas de Economía de la Salud: Avances en la gestión sanitaria …, 2000 | 17 | 2000 |
| Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model F Antoñanzas, CA Juárez-Castelló, R Rodríguez-Ibeas Health Economics Review 11 (1), 1-12, 2021 | 13 | 2021 |
| La eficacia de los equipos de trabajo y su medición N Fernández Losa, CA Juárez-Castelló Boletín de Estudios Económicos 56 (172), 57, 2001 | 12 | 2001 |
| EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data? F Antoñanzas, CA Juárez-Castelló, R Rodríguez-Ibeas The European Journal of Health Economics 19 (7), 905-907, 2018 | 11 | 2018 |
| Efficiency of Diagnostic Testing for Helicobacter pylori Infections—A Systematic Review. Antibiotics 2021, 10, 55 P Rojas García, S van der Pol, ADI van Asselt, M Postma, ... Antibiotics (Basel, Switzerland) 10 ((1) 55), 2021 | 9 | 2021 |
| Clínica y epidemiología de la Insuficiencia Cardiaca Congestiva (ICC): un análisis de costes= Clinical and epidemiological of congestive heart failure (CHF): An analysis of costs F Antonanzas Villar, F Anton Botella, L Echeverria Echarri, ... Clinica cardiovascular 16 (1), 27-34, 1998 | 9 | 1998 |
| Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad F Antoñanzas, CA Juárez-Castelló, R Rodríguez-Ibeas The European Journal of Health Economics 12 (5), 393-395, 2011 | 8 | 2011 |
| Should the patent system for pharmaceuticals be replaced? A theoretical approach F Antoñanzas, R Rodríguez-Ibeas, CA Juárez-Castelló Expert review of pharmacoeconomics & outcomes research 14 (5), 617-626, 2014 | 7 | 2014 |
Juan Oliva MorenoUniversidad de Castilla La ManchaVerified email at uclm.es
